Abstract
Background/Objectives
To investigate post-enucleation outcomes and assess the effect of extrascleral extension (ESE) on these outcomes for patients with uveal melanoma (UM) managed at a tertiary referral centre in Scotland.
Subjects/Methods
Retrospective review of all cases of UM managed by the Scottish Ocular Oncology Service for which enucleation was undertaken between 13/03/2008 and 31/12/2020. Primary outcomes were length of survival, time-to-metastasis (TTM) and local recurrence rate. Secondary outcomes were the effects of the presence of ESE, ESE size, and the use of adjuvant external beam radiotherapy (EBRT) on the primary outcomes.
Results
Of 172 enucleated UMs, 32 (18.6%) had ESE. Over a median follow-up period of 33.7 months (range = 1.1–163.7 months), 91 (52.9%) patients died. The median length of all-cause survival of 54.1 months (range = 1.1–163.7 months). One-year, 5-year, and 10-year survival rates were 84.8%, 49.1%, and 30.9%, respectively. Eighty-four (49.7%) patients had metastatic disease. The median TTM of 42.2 months (range = 0.4–106.8 months). Proportions of patients who developed metastases within 1-year, 5-years and 10-years post-enucleation were 22.7%, 52.8%, and 71.8%, respectively. There was one instance of local orbital recurrence. ESE was associated with a significantly shorter length of survival (p = 0.03). There was a trend towards a shorter length of survival and TTM with ESE > 5 mm and those who received adjuvant EBRT.
Conclusions
ESE was present in one-sixth of our cohort and was associated with a significantly shorter length of survival, particularly in the presence of ESE > 5 mm or high-risk characteristics warranting adjuvant EBRT. This data will aid prognostication of the patients in our service.
Similar content being viewed by others
Log in or create a free account to read this content
Gain free access to this article, as well as selected content from this journal and more on nature.com
or
Data availability
Anonymised datasets generated during and/or analysed during the current study are available from the corresponding author on reasonable request.
References
Virgili G, Gatta G, Ciccolallo L, Capocaccia R, BiggeriZ A, Crocetti E, et al. Incidence of uveal melanoma in Europe. Ophthalmology 2007;114:2309–15.
McLaughlin CC, Wu X-C, Jemal A, Martin HJ, Roche LM, Chen VW. Incidence of noncutaneous melanomas in the U.S. Cancer [Internet] 2005;103:1000–7. https://doi.org/10.1002/cncr.20866.
Beasley AB, Preen DB, McLenachan S, Gray ES, Chen FK. Incidence and mortality of uveal melanoma in Australia (1982–2014). Br J Ophthalmol. 2021. https://doi.org/10.1136/bjophthalmol-2021-319700.
Jamison A, Bhatti LA, Sobti MM, Chadha V, Cauchi P, Kemp EG. Uveal melanoma-associated survival in Scotland. Eye (Lond). 2019;33:1699–706.
Collaborative Ocular Melanoma Study Group. The COMS randomized trial of iodine 125 brachytherapy for choroidal melanoma: V. Twelve-year mortality rates and prognostic factors: COMS report No. 28. Arch Ophthalmol 2006;124:1684–93.
Shields C, Dockery P, Mayro E, Bas Z, Yaghy A, Lally S, et al. Conditional survival of uveal melanoma using The Cancer Genome Atlas (TCGA) classification (Simplified Version) in 1001 cases. Saudi J Ophthalmol. 2022. https://doi.org/10.4103/SJOPT.SJOPT_69_21.
Kaliki S, Shields CL. Uveal melanoma: relatively rare but deadly cancer. Eye [Internet] 2017;31:241–57. http://www.nature.com/articles/eye2016275.
Diener-West M, Earle J, Fine S, Hawkins B, Moy C, Reynolds S, et al. Collaborative Ocular Melanoma Study Group: The COMS randomized trial of iodine 125 brachytherapy for choroidal melanoma, III. Arch Ophthalmol. 2001;119:969–82.
Li W, Gragoudas ES, Egan KM. Metastatic melanoma death rates by anatomic site after proton beam irradiation for uveal melanoma. Arch Ophthalmol (Chic, Ill 1960) [Internet] 2000;118:1066–70. http://www.ncbi.nlm.nih.gov/pubmed/10922199.
van Beek JGM, Koopmans AE, Vaarwater J, de Rooi JJ, Paridaens D, Naus NC, et al. The Prognostic Value of Extraocular Extension in Relation to Monosomy 3 and Gain of Chromosome 8q in Uveal Melanoma. Investig Opthalmology Vis Sci [Internet] 2014;55:1284 http://iovs.arvojournals.org/article.aspx?
Kujala E, Makitie T, Kivela T. Very Long-Term Prognosis of Patients with Malignant Uveal Melanoma. Investig Opthalmology Vis Sci [Internet] 2003;44:4651 http://iovs.arvojournals.org/article.aspx?
Singh A, Shields C, Shields J. Prognostic factors in uveal melanoma. Clin Ophthalmic Oncol Uveal Tumors. 2014;11:239–48.
Coupland SE, Campbell I, Damato B. Routes of Extraocular Extension of Uveal Melanoma. Risk Factors and Influence on Survival Probability. Ophthalmology 2008;115:1778–85.
Hykin PG, Mccartney ACE, Plowman PN, Hungerford JL. Postenucleation orbital radiotherapy for the treatment of malignant melanoma of the choroid with extrascleral extension [Internet]. 74, Br J Ophthalmol. 1990 [cited 2020 Oct 9]. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1041975/pdf/brjopthal00575-0044.pdf.
Roelofs KA, Cohen VML, Sagoo MS, Plowman PN, Negretti GS, O’Day R, et al. Adjuvant External Beam Radiotherapy Following Enucleation of Eyes With Extraocular Extension From Uveal Melanoma. Ophthalmic Plast Reconstr Surg [Internet]. 2020 [cited 2020 Oct 16];Publish Ah. https://journals.lww.com/10.1097/IOP.0000000000001800
Mudhar HS, Coupland SE. Dataset for histopathological reporting of uveal melanoma. 5th ed [Internet]. 2021. Available from: https://www.rcpath.org/uploads/assets/7baa5a48-e3fc-4dc8-b0e36c5a5c9a194b/778f7dc3-135a-4590-aaeec103048a492f/G056-Dataset-for-histopathological-reporting-of-uveal-melanoma.pdf.
Amin MB, Edge SB, Greene FL, Byrd DR, Brookland RK, Washington MK, et al. editors. AJCC Cancer Staging Manual. 8th ed. New York: Springer; 2016. p. 805–17.
Cursiefen C, Kruse FE, Naumann GOH. Cornea and limbus. Appl Pathol Ophthalmic Microsurg. Berlin: Springer; 2008. p. 97–130.
Heindl LM, Hofmann TN, Adler W, Knorr HLJ, Holbach LM, Naumann GOH, et al. Intraocular tumor-associated lymphangiogenesis a novel prognostic factor for ciliary body melanomas with extraocular extension? Ophthalmology 2010;117:334–42. https://doi.org/10.1016/j.ophtha.2009.06.057.
Burris CKH, Papastefanou VP, Thaung C, Restori M, Arora AK, Sagoo M, et al. Detection of Extrascleral Extension in Uveal melanoma with Histopathological Correlation. Orbit 2018;37:287–92. https://doi.org/10.1080/01676830.2017.1423083.
Negretti GS, Gurudas S, Gallo B, Damato B, Arora AK, Sivaprasad S, et al. Survival analysis following enucleation for uveal melanoma. Eye. 2022;36:1669–74.
Bergeron E, Lihimdi N, Bergeron D, Landreville S. Orbital recurrence of iris melanoma 21 years after enucleation. BMJ Case Rep [Internet]. 2017 [cited 2021 Dec 14];2017. http://www.ncbi.nlm.nih.gov/pubmed/28882848.
Mittica N, Vemuganti GK, Duffy M, Torczynski E, Edward DP. Late orbital recurrence of a choroidal melanoma following internal resection: Report of a case and review of the literature. Surv Ophthalmol. 2003;48:181–90.
Gallie BL, Simpson ER, Saakyan S, Amiryan A, Valskiy V, Finger PT, et al. Local Recurrence Significantly Increases the Risk of Metastatic Uveal Melanoma. Ophthalmology 2016;123:86–91.
Jampol LM, Moy CS, Murray TG, Reynolds SM, Albert DM, Schachat AP, et al. The COMS randomized trial of iodine 125 brachytherapy for choroidal melanoma: IV. Local treatment failure and enucleation in the first 5 years after brachytherapy. COMS Rep. no 19 Ophthalmol 2002;109:2197–206.
Wang H, Zhang R, Wang Y, Chen R, Liu Y, Li Y, et al. Retrospective analysis of secondary enucleation for uveal melanoma after plaque radiotherapy. BMC Ophthalmol. 2022;22:163.
Author information
Authors and Affiliations
Contributions
Conceptualisation of study aims: VC; Data acquisition: FR, DS, TM; Data extraction, statistical analysis, data interpretation, preparation of paper: DS, TM; Critical review of paper: FR, JC, PC, VC.
Corresponding author
Ethics declarations
Competing interests
The authors declare no competing interests.
Additional information
Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Rights and permissions
Springer Nature or its licensor (e.g. a society or other partner) holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law.
About this article
Cite this article
Sarode, D., McClay, T., Roberts, F. et al. Post-enucleation outcomes of patients with uveal melanoma in Scotland. Eye 37, 988–994 (2023). https://doi.org/10.1038/s41433-022-02280-3
Received:
Revised:
Accepted:
Published:
Issue date:
DOI: https://doi.org/10.1038/s41433-022-02280-3
This article is cited by
-
Clinicopathological evaluation of secondary conjunctival pigmentations following enucleation
International Ophthalmology (2025)
